Financial Ratios Guardant Health, Inc.
Equities
GH
US40131M1099
Medical Equipment, Supplies & Distribution
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 87.89 USD | +0.81% |
|
-2.45% | -13.57% |
| Mar. 11 | Guardant Health, Inc. Presents at Barclays 28th Annual Global Healthcare Conference, Mar-11-2026 01:00 PM | |
| Mar. 11 | Braidwell, Karnal and Kreiter's AI healthcare fund, surged 28% last year | RE |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | -11.48 | -17.84 | -17.64 | -16.95 | -15.59 | |||||
Return on Total Capital | -12.15 | -19.73 | -20.36 | -20.47 | -19.43 | |||||
Return On Equity % | -38.47 | -185.65 | -438.12 | -4.58K | 348.42 | |||||
Return on Common Equity | -41.75 | -185.65 | -438.12 | -4.58K | 348.42 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 67.11 | 65.23 | 59.74 | 60.79 | 64.46 | |||||
SG&A Margin | 106.66 | 103.17 | 79.98 | 73.75 | 71.8 | |||||
EBITDA Margin % | -104.04 | -113.1 | -77.37 | -54.29 | -40.38 | |||||
EBITA Margin % | -109.49 | -120.54 | -84.5 | -59.73 | -44.26 | |||||
EBIT Margin % | -110 | -121.1 | -84.98 | -60.02 | -44.43 | |||||
Income From Continuing Operations Margin % | -102.98 | -145.61 | -85.02 | -59.05 | -42.39 | |||||
Net Income Margin % | -108.57 | -145.61 | -85.02 | -59.05 | -42.39 | |||||
Net Avail. For Common Margin % | -108.57 | -145.61 | -85.02 | -59.05 | -42.39 | |||||
Normalized Net Income Margin | -74.08 | -89.03 | -49.2 | -33.04 | -25.33 | |||||
Levered Free Cash Flow Margin | -33.05 | -65.75 | -31.36 | -19.87 | -8.97 | |||||
Unlevered Free Cash Flow Margin | -33.3 | -65.96 | -31.54 | -20 | -8.72 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.17 | 0.24 | 0.33 | 0.45 | 0.56 | |||||
Fixed Assets Turnover | 1.8 | 1.37 | 1.75 | 2.54 | 3.36 | |||||
Receivables Turnover (Average Receivables) | 4.95 | 4.61 | 6.06 | 7.43 | 7.92 | |||||
Inventory Turnover (Average Inventory) | 4.6 | 3.8 | 4 | 4.36 | 4.45 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 5.72 | 6.17 | 6.54 | 4.68 | 4.84 | |||||
Quick Ratio | 5.29 | 5.74 | 6.11 | 4.21 | 4.42 | |||||
Operating Cash Flow to Current Liabilities | -1.07 | -1.6 | -1.58 | -1.06 | -0.61 | |||||
Days Sales Outstanding (Average Receivables) | 73.73 | 79.13 | 60.2 | 49.29 | 46.11 | |||||
Days Outstanding Inventory (Average Inventory) | 79.27 | 96.05 | 91.27 | 84.01 | 82.08 | |||||
Average Days Payable Outstanding | 34.75 | 110.61 | 92.75 | 55.27 | 46.65 | |||||
Cash Conversion Cycle (Average Days) | 118.25 | 64.56 | 58.72 | 78.02 | 81.53 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 212.98 | 2.28K | 853.12 | -956.74 | -1.72K | |||||
Total Debt / Total Capital | 68.05 | 95.79 | 89.51 | 111.67 | 106.16 | |||||
LT Debt/Equity | 210.99 | 2.24K | 835.51 | -935.82 | -1.69K | |||||
Long-Term Debt / Total Capital | 67.41 | 94.26 | 87.66 | 109.23 | 104.45 | |||||
Total Liabilities / Total Assets | 70.74 | 96.26 | 91.12 | 109.4 | 104.93 | |||||
EBIT / Interest Expense | -159.49 | -211.24 | -185.89 | -171.87 | -111.96 | |||||
EBITDA / Interest Expense | -141.26 | -186.19 | -157.74 | -143.4 | -93.14 | |||||
(EBITDA - Capex) / Interest Expense | -170.38 | -216.25 | -165.68 | -156.99 | -105.53 | |||||
Total Debt / EBITDA | -3.77 | -2.85 | -3.33 | -3.61 | -4.71 | |||||
Net Debt / EBITDA | 0.71 | -0.75 | -0.46 | -1.34 | -1.4 | |||||
Total Debt / (EBITDA - Capex) | -3.13 | -2.46 | -3.17 | -3.3 | -4.16 | |||||
Net Debt / (EBITDA - Capex) | 0.59 | -0.64 | -0.43 | -1.22 | -1.24 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 30.32 | 20.31 | 25.45 | 31.04 | 32.88 | |||||
Gross Profit, 1 Yr. Growth % | 29.12 | 16.94 | 14.9 | 33.34 | 40.91 | |||||
EBITDA, 1 Yr. Growth % | 62.73 | 30.79 | -13.29 | -8.49 | -0.91 | |||||
EBITA, 1 Yr. Growth % | 61.6 | 32.46 | -11.21 | -7.78 | -1.31 | |||||
EBIT, 1 Yr. Growth % | 61.21 | 32.45 | -11.12 | -7.84 | -1.42 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 56.23 | 70.12 | -26.76 | -8.98 | -4.61 | |||||
Net Income, 1 Yr. Growth % | 59.85 | 61.36 | -26.76 | -8.98 | -4.61 | |||||
Normalized Net Income, 1 Yr. Growth % | 70.54 | 44.58 | -30.11 | -12.41 | 2.14 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 53.84 | 60 | -33.17 | -16.96 | -6.61 | |||||
Accounts Receivable, 1 Yr. Growth % | 83.22 | -0.41 | -8.71 | 24.18 | 25.03 | |||||
Inventory, 1 Yr. Growth % | 35.03 | 68.21 | 20.06 | 14.75 | 20.81 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 213.51 | 8.93 | -11.47 | -7.81 | 9.2 | |||||
Total Assets, 1 Yr. Growth % | -2.96 | -26.97 | 10.96 | -16.84 | 35.54 | |||||
Tangible Book Value, 1 Yr. Growth % | -50.94 | -92.8 | 224.19 | -202.24 | 35.26 | |||||
Common Equity, 1 Yr. Growth % | -50.33 | -90.67 | 163.68 | -188 | -28.89 | |||||
Cash From Operations, 1 Yr. Growth % | 101.12 | 48.06 | 5.01 | -26.19 | -22.97 | |||||
Capital Expenditures, 1 Yr. Growth % | 107.43 | 3.23 | -73.55 | 71.26 | 37.68 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 62.87 | 139.36 | -39.49 | -17.6 | -40.78 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 60.42 | 138.3 | -39.36 | -17.51 | -41.79 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 32.02 | 25.21 | 22.85 | 28.22 | 31.96 | |||||
Gross Profit, 2 Yr. CAGR % | 32.12 | 22.88 | 15.91 | 23.78 | 37.08 | |||||
EBITDA, 2 Yr. CAGR % | 134.05 | 45.89 | 5.95 | -11.17 | -4.88 | |||||
EBITA, 2 Yr. CAGR % | 123.81 | 46.31 | 7.93 | -9.75 | -4.7 | |||||
EBIT, 2 Yr. CAGR % | 123.37 | 46.12 | 7.98 | -9.73 | -4.78 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 138.13 | 63.03 | 11.63 | -18.35 | -6.82 | |||||
Net Income, 2 Yr. CAGR % | 131.57 | 60.6 | 8.71 | -18.35 | -6.82 | |||||
Normalized Net Income, 2 Yr. CAGR % | 132.12 | 57.57 | 0.11 | -21.89 | -5.52 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 118.98 | 56.89 | 3.4 | -25.51 | -11.94 | |||||
Accounts Receivable, 2 Yr. CAGR % | 42.65 | 35.08 | -4.65 | 6.47 | 24.61 | |||||
Inventory, 2 Yr. CAGR % | 42.15 | 50.71 | 42.11 | 17.37 | 17.74 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 107.64 | 84.8 | -1.8 | -9.66 | 0.34 | |||||
Total Assets, 2 Yr. CAGR % | 51.34 | -15.82 | -9.98 | -3.94 | 6.17 | |||||
Tangible Book Value, 2 Yr. CAGR % | -10.29 | -81.21 | -51.7 | 82.06 | 17.6 | |||||
Common Equity, 2 Yr. CAGR % | -10.12 | -78.47 | -50.4 | 52.33 | -20.89 | |||||
Cash From Operations, 2 Yr. CAGR % | 110.58 | 72.56 | 24.69 | -11.96 | -24.6 | |||||
Capital Expenditures, 2 Yr. CAGR % | 100.22 | 46.34 | -47.75 | -32.7 | 53.56 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 55.58 | 97.44 | 19.69 | -29.52 | -30.17 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 57.32 | 95.52 | 19.55 | -29.4 | -30.84 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 60.34 | 28 | 25.29 | 25.52 | 29.75 | |||||
Gross Profit, 3 Yr. CAGR % | 74.2 | 26.85 | 20.16 | 21.45 | 29.24 | |||||
EBITDA, 3 Yr. CAGR % | 65.47 | 92.78 | 22.24 | 1.06 | -7.95 | |||||
EBITA, 3 Yr. CAGR % | 64.42 | 87.91 | 23.47 | 2.56 | -7.09 | |||||
EBIT, 3 Yr. CAGR % | 64.14 | 87.66 | 23.41 | 2.58 | -7.11 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 65.9 | 112.88 | 24.86 | 4.28 | -14.01 | |||||
Net Income, 3 Yr. CAGR % | 68.32 | 105.3 | 23.62 | 2.46 | -14.01 | |||||
Normalized Net Income, 3 Yr. CAGR % | 70.25 | 98.23 | 19.84 | -4.1 | -14.66 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 12.69 | 97.23 | 18.04 | -3.89 | -19.67 | |||||
Accounts Receivable, 3 Yr. CAGR % | 39.87 | 26.55 | 18.54 | 4.13 | 12.33 | |||||
Inventory, 3 Yr. CAGR % | 49.74 | 50.35 | 39.71 | 32.33 | 18.51 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 116.34 | 67.46 | 44.6 | -3.84 | -3.76 | |||||
Total Assets, 3 Yr. CAGR % | 55.4 | 18.7 | -7.7 | -12.33 | 7.74 | |||||
Tangible Book Value, 3 Yr. CAGR % | 9.7 | -61.31 | -51.45 | -37.98 | 64.89 | |||||
Common Equity, 3 Yr. CAGR % | 10.11 | -57.76 | -50.38 | -39.95 | 18.17 | |||||
Cash From Operations, 3 Yr. CAGR % | 42.53 | 87.25 | 46.23 | 4.69 | -15.8 | |||||
Capital Expenditures, 3 Yr. CAGR % | 54.86 | 60.55 | -17.26 | -22.38 | -14.56 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 23.23 | 79.6 | 32.63 | 5.94 | -33.2 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 24.04 | 80.67 | 31.86 | 5.9 | -33.89 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 71.41 | 55.25 | 44.14 | 28.08 | 27.92 | |||||
Gross Profit, 5 Yr. CAGR % | 140.37 | 74.3 | 48.01 | 25.61 | 26.66 | |||||
EBITDA, 5 Yr. CAGR % | 57.46 | 49.36 | 38.44 | 41.41 | 10.67 | |||||
EBITA, 5 Yr. CAGR % | 56.31 | 49.07 | 38.94 | 40.14 | 11.41 | |||||
EBIT, 5 Yr. CAGR % | 56.45 | 49.21 | 38.82 | 40.04 | 11.34 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 52.84 | 51.06 | 41.59 | 45.1 | 11.07 | |||||
Net Income, 5 Yr. CAGR % | 54.46 | 51.06 | 41.32 | 41.97 | 10.4 | |||||
Normalized Net Income, 5 Yr. CAGR % | 57.2 | 53.5 | 37.67 | 36.58 | 9.07 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 2.52 | -1.96 | 8.88 | 33.61 | 4.99 | |||||
Accounts Receivable, 5 Yr. CAGR % | 94.65 | 50.05 | 19.99 | 18.1 | 20.93 | |||||
Inventory, 5 Yr. CAGR % | 61.77 | 47.92 | 46.64 | 36.17 | 30.47 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 90.13 | 84.4 | 57.73 | 30.83 | 24.94 | |||||
Total Assets, 5 Yr. CAGR % | 80.03 | 36.25 | 24.91 | 9.07 | -2.38 | |||||
Tangible Book Value, 5 Yr. CAGR % | 44.3 | -25.75 | -20.98 | -28.11 | -30.83 | |||||
Common Equity, 5 Yr. CAGR % | 45.09 | -20.66 | -19.96 | -29.44 | -40.2 | |||||
Cash From Operations, 5 Yr. CAGR % | 41.61 | 33.77 | 35.11 | 38.46 | 12.2 | |||||
Capital Expenditures, 5 Yr. CAGR % | 111.67 | 63.25 | 0.28 | 13.39 | 5.96 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | - | 39.32 | 21.8 | 23.54 | 3.05 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | - | 40.27 | 22.22 | 24.07 | 2.01 |
- Stock Market
- Equities
- GH Stock
- Financials Guardant Health, Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















